Significant Differences in Markers of Oxidant Injury between Idiopathic and Bronchopulmonary-Dysplasia-Associated Pulmonary Hypertension in Children

Table 2

Medical therapy of pulmonary hypertension patients.

	IPH	PH due to BPD	P value
N	4	12
Home	1	8	.13^*
Oxygen
(No. of patients)
Epoprostenol	3	2	.06^*
(No. of patients)
Bosentan	1	1	.52^*
(No. of patients)
Sildenafil	3	11	.45^*
(No. of patients)
Months on	17.5 (4–27.5)	20 (12–29)	.99^**
Therapy^†

^∗𝑃 value based on Fisher’s exact test.
^∗∗𝑃 values based on Mann-Whitney U test.
^†Data expressed as median (IQR).